194 related articles for article (PubMed ID: 18172070)
1. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
[TBL] [Abstract][Full Text] [Related]
2. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
3. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
4. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
5. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA
Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutations in conjunctival melanoma.
Gear H; Williams H; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma.
Maat W; Beiboer SH; Jager MJ; Luyten GP; Gruis NA; van der Velden PA
Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1291-8. PubMed ID: 18385040
[TBL] [Abstract][Full Text] [Related]
10. The T1799A point mutation is present in posterior uveal melanoma.
Janssen CS; Sibbett R; Henriquez FL; McKay IC; Kemp EG; Roberts F
Br J Cancer; 2008 Nov; 99(10):1673-7. PubMed ID: 18985043
[TBL] [Abstract][Full Text] [Related]
11. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Burger M; Denzinger S; Hammerschmied C; Tannapfel A; Maderstorfer A; Wieland WF; Hartmann A; Stoehr R
Eur Urol; 2006 Nov; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100
[TBL] [Abstract][Full Text] [Related]
12. Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
[TBL] [Abstract][Full Text] [Related]
13. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
14. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
Deichmann M; Thome M; Benner A; Näher H
Oncology; 2004; 66(5):411-9. PubMed ID: 15331929
[TBL] [Abstract][Full Text] [Related]
15. The T1799A BRAF mutation is present in iris melanoma.
Henriquez F; Janssen C; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4897-900. PubMed ID: 17962436
[TBL] [Abstract][Full Text] [Related]
16. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
17. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Bloethner S; Chen B; Hemminki K; Müller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
Carcinogenesis; 2005 Jul; 26(7):1224-32. PubMed ID: 15760917
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
Cui Y; Borysova MK; Johnson JO; Guadagno TM
Cancer Res; 2010 Jan; 70(2):675-84. PubMed ID: 20068179
[TBL] [Abstract][Full Text] [Related]
19. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
[TBL] [Abstract][Full Text] [Related]
20. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
